We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

This FTSE 100 giant is going through the mire! Should I buy the dip?

Sumayya Mansoor explains why this FTSE 100 consumer goods giant is currently on her radar. But is it one for her to buy or avoid?

| More on:
Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

FTSE 100 incumbent Reckitt (LSE: RKT) was once seen as a no-brainer defensive buy for many investors.

Things haven’t been great recently – more on that later – so is there an opportunity for me to buy cheaper shares with a view to a recovery toward former glories? Let’s take a closer look.

Should you buy Reckitt Benckiser Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Tough times

As a reminder, Reckitt is one of the largest consumer goods businesses out there. With a raft of popular brands under its belt, including Dettol, Calgon, Air Wick, Durex, Nurofen, and more, it’s no wonder it’s been a popular stock in the past.

Unfortunately, recent issues have prompted the shares to fall sharply. Over a 12-month period they’re down 22% from 5,826p, to current levels of 4,501p.

What’s happened?

Going back to 2017, the acquisition of baby formula business Mead Johnson Nutrition for over $16bn was the catalyst for Reckitt’s struggles, in my view. As well as arguably overpaying, Reckitt also inherited legal troubles linked to the firm’s products, which have been argued as being dangerous for babies. An Illinois court awarded a woman $60m for the death of her baby linked to the use of Mead Johnson’s Enfamil formula. The Reckitt share price fell by 15% alone when this happened.

Moving forward, there are still a few legal battles raging on. It seems the ill-fated acquisition has set Reckitt on an unwanted and costly course. I’ll be keeping a close eye on things.

The other side of the coin

Despite this rather large bump in the road, I still think Reckitt is a quality business. As mentioned earlier, its popular brands carry sway with consumers across the world. This is another bonus, as this vast presence could help boost earnings and returns.

Next, its decision – a bit like competitor Unilever – to streamline its brand portfolio and focus on its best-selling ones, could help the business recover from other issues. It’s a smart move, in my eyes.

Furthermore, Reckitt continues to look to expand into new territories to grow the business. This could be another money spinner that could help boost earnings and returns, as well as repair the damage mentioned earlier.

Finally, the shares are now trading at dirt-cheap levels, if you ask me. A price-to-earnings ratio of close to 13 is way below a five-year average of over 21. This is a great entry point that has tempted me today. Plus, a dividend yield of 4.4% is enticing. However, I do understand that dividends are never guaranteed. Also, this higher yield is the result of a share price drop.

What I’m doing now

It’s a tricky call for me to make, if I’m honest. I do believe there is a fantastic company in Reckitt. However, I’m not oblivious to the recent challenges, and what the poor decision of this acquisition has done to the business and its outlook.

Ultimately, ongoing lawsuits and the prospect of millions, or even more, in fines and litigation to come doesn’t sit well with me. I’m not planning on buying any shares right now but will keep a close eye on developments. I may revisit my position soon.

Sumayya Mansoor has no position in any of the shares mentioned. The Motley Fool UK has recommended Reckitt Benckiser Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up nearly 1,400% in 5 years! But are Rolls-Royce shares still secretly undervalued?

After skyrocketing, Rolls-Royce shares are now near an all-time high, but could the engineering giant still have more room to…

Read more »

Happy senior couple hugging and enjoying retirement at home
Investing Articles

By mid-2027, analysts expect £5,000 in Barclays shares to be worth…

Barclays shares have outperformed the FTSE 100 by a wide margin over the last year. And City analysts expect to…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Near 5-year lows, here’s what the experts say about the Diageo share price

Ben McPoland's questioning his sanity after investing in Diageo. Where do institutional analysts see its share price heading over the…

Read more »

British Airways cabin crew with mobile device
Investing Articles

Up 165% but still with a P/E of 7.9. Is the IAG share price a generational bargain?

The IAG share price has been on fire for the last two years, delivering some of the biggest returns in…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Here’s the latest Vodafone share price forecasts for 2027

Up 35% in 12 months, the Vodafone share price is beating the stock market right now, but can this momentum…

Read more »